Biechele Royce Advisors lessened its holdings in Sanofi SA (NYSE:SNY) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 40,276 shares of the company’s stock after selling 1,103 shares during the quarter. Sanofi accounts for approximately 1.3% of Biechele Royce Advisors’ investment portfolio, making the stock its 26th biggest position. Biechele Royce Advisors’ holdings in Sanofi were worth $1,748,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Essex Savings Bank acquired a new stake in shares of Sanofi in the 4th quarter valued at $30,000. Lavaca Capital LLC acquired a new stake in shares of Sanofi in the 4th quarter valued at $51,000. Focused Wealth Management Inc boosted its holdings in shares of Sanofi by 33.2% in the 4th quarter. Focused Wealth Management Inc now owns 1,204 shares of the company’s stock valued at $52,000 after purchasing an additional 300 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Sanofi by 48.1% in the 4th quarter. Parallel Advisors LLC now owns 1,760 shares of the company’s stock valued at $76,000 after purchasing an additional 572 shares in the last quarter. Finally, Girard Partners LTD. acquired a new stake in shares of Sanofi in the 3rd quarter valued at $154,000. 7.04% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts recently weighed in on SNY shares. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Monday, October 15th. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. ValuEngine raised Sanofi from a “sell” rating to a “hold” rating in a report on Wednesday, October 17th. Wolfe Research started coverage on Sanofi in a report on Tuesday, October 23rd. They set a “market perform” rating on the stock. Finally, Barclays raised Sanofi from an “underweight” rating to an “equal weight” rating in a report on Thursday, November 1st. Eight analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $51.00.
NYSE SNY opened at $42.33 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. Sanofi SA has a twelve month low of $37.43 and a twelve month high of $45.62. The firm has a market cap of $106.62 billion, a P/E ratio of 13.52, a PEG ratio of 2.41 and a beta of 0.67.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Thursday, February 7th. The company reported $0.63 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.01. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The company had revenue of $9 billion for the quarter, compared to the consensus estimate of $9 billion. During the same quarter last year, the business posted $1.06 EPS. Sanofi’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, analysts forecast that Sanofi SA will post 3.1 earnings per share for the current fiscal year.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: What is a Market Correction?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.